CABALETTA BIO INC (CABA) Stock News
NASDAQ:CABA - Nasdaq - US12674W1099 - Common Stock - Currency: USD
CABA Latest News, Press Relases and Analysis
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across...
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and...
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and...
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
PHILADELPHIA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cabaletta Bio (NASDAQ:CABA) just reported results for the second quarter of 202...
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q2 2024
CABA stock results show that Cabaletta Bio missed analyst estimates for earnings per share the second quarter of 2024.
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
– Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in...
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
PHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical...
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...